Related Experiment Videos
The effect of antihypertensive drugs on erectile function: a proposed management algorithm
1Department of Internal Medicine, University of Thrace, Alexandroupolis, Greece. michalisdoumas@yahoo.co.uk
Journal of Clinical Hypertension (Greenwich, Conn.)
|May 12, 2006
Summary
Certain blood pressure medications can cause erectile dysfunction, leading to treatment nonadherence. Newer drugs like angiotensin receptor blockers may improve erectile function, and phosphodiesterase-5 inhibitors offer a safe treatment option for hypertensive patients.
Area of Science:
- Pharmacology
- Urology
- Cardiology
Background:
- Hypertension pharmacologic management is linked to erectile dysfunction (ED).
- ED is a primary cause of nonadherence to antihypertensive therapy.
- Older antihypertensives negatively impact erectile function, while newer agents show neutral or beneficial effects.
Purpose of the Study:
- To review the impact of antihypertensive medications on erectile function.
- To discuss the safety and efficacy of phosphodiesterase-5 inhibitors in hypertensive patients with ED.
- To provide guidance on managing ED in the context of hypertension treatment.
Main Methods:
- Literature review of studies on antihypertensive drugs and erectile function.
- Analysis of clinical data on phosphodiesterase-5 inhibitors in hypertensive populations.
- Evaluation of treatment strategies for ED in patients with hypertension.
Main Results:
- Older antihypertensives (central-acting, beta blockers, diuretics) impair erectile function.
- Newer agents (calcium antagonists, ACE inhibitors) have neutral effects.
- Angiotensin receptor blockers show preliminary beneficial effects on erectile function.
- Phosphodiesterase-5 inhibitors are safe and effective for hypertensive patients, with caution for alpha-blocker use.
Conclusions:
- Physicians can manage ED caused by antihypertensives by adding phosphodiesterase-5 inhibitors or switching to angiotensin receptor blockers.
- Optimizing antihypertensive therapy can improve adherence and erectile function.
- Phosphodiesterase-5 inhibitors represent a valuable therapeutic option for hypertensive patients experiencing ED.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...